Name: Diacerein
Brand: Selleck Chemicals
SKU: S4267
Availability: InStock
Rating: 5 (7 reviews)

Jump to

Quality Control

Batch: Purity: 99.25%

99.25

Related Targets	PD-1/PD-L1 CXCR STING AhR Immunology & Inflammation related CD markers Anti-infection Antioxidant COX Histamine Receptor
Other Interleukins Inhibitors	SC144 Ossirene (AS101) Apilimod mesylate Ac-YVAD-cmk EC330 Raleukin Diethyl phosphate Sodium Thiocyanate IQ 3 LMT-28

Solubility

In vitro
Batch:

DMSO : 18 mg/mL (48.87 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	368.29	Formula	C₁₉H₁₂O₈	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	13739-02-1	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	CC(=O)OC1=CC=CC2=C1C(=O)C3=C(C2=O)C=C(C=C3OC(=O)C)C(=O)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro	Diacerein significantly inhibits LPS-induced IL-1beta production by synovial tissue and cartilage. This compound (1 μM) has a significantly less inhibitory effect on cartilage synthesis than culture media containing LPS only. It decreases NO release in synovial tissue and cartilage media and increases IL-1ra levels in cartilage culture media. This chemical (10 μM) enhances the expression of TGF-beta1 and TGF-beta2 in cultured bovine articular chondrocytes. It reduces, in a dose-dependent manner, the interleukin-1-beta (IL-1beta)-induced MMP-13 production in osteoarthritic subchondral bone. This agent significantly reduces the activity of MMP-13 and cathepsin K in osteoclasts. It effectively blocks the IL-1beta effect on the osteoclast differentiation process and the survival of mature osteoclasts.
In vivo	Diacerein (100 mg/kg/day) significantly suppresses the paw edema and the increase in serum mucoprotein in the adjuvant-induced arthritic rats. This compound (30 mg/kg/day) combined with Naproxen (3 mg/kg/day) results in significantly greater anti-inflammatory activity than with naproxen alone in the adjuvant-induced arthritic rats. It (100 mg/kg/day) also significantly prevents bone loss and reduces the serum alkaline phosphatase and decreases the excretion of urinary hydroxyproline in the ovariectomized rats. This chemical (25 mg/kg) decreases the thickness of cartilage and subchondral bone in the lesion (middle) zone of the lateral tibial plateau in Merino wethers.
References	[1] https://pubmed.ncbi.nlm.nih.gov/10329302/ [2] https://pubmed.ncbi.nlm.nih.gov/10329300/ [3] https://pubmed.ncbi.nlm.nih.gov/18578867/ [4] https://pubmed.ncbi.nlm.nih.gov/12126975/ [5] https://pubmed.ncbi.nlm.nih.gov/11327258/

Applications

Methods	Biomarkers	Images	PMID
Western blot	Cyclin B1 / CDK1 / CDK2 AKT / p-AKT / p38 / p-p38 / p53 p-STAT3 / STAT3 MDM2 / CDC2		26555773

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-01-20)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07352306	NOT_YET_RECRUITING	Psoriasis Vulgaris	Cairo University	2026-02-01	PHASE4
NCT04318041	RECRUITING	Knee Osteoarthritis	TRB Chemedica	2020-11-22	PHASE3
NCT07199933	NOT_YET_RECRUITING	MAFLD	Hongyan Wu	2025-10-01
NCT06073132	ACTIVE_NOT_RECRUITING	Generalized Epidermolysis Bullosa Simplex	TWi Biotechnology, Inc.	2024-04-04	PHASE2; PHASE3
NCT07549386	COMPLETED	Pain Management; Osteoarthritis	Laboratorios Liomont	2024-05-24	PHASE3
NCT06912035	COMPLETED	Uncontrolled Diabetes; Diabetes Mellitus Type 2	Universitas Sriwijaya	2024-06-21	PHASE2; PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Diacerein Interleukins inhibitor

Chemical Structure

Molecular Weight: 368.29